Cargando…

The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen

It has been 18 months now since the world-wide outbreak of COVID 19 (Corona Virus Disease 19) and still the ongoing research is being done for disease specific medicines. During June 2020 to August 2020, an attempt was made to explore if an add-on Ayurveda regimen comprising of Dasamoolkadutrayadi K...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanjarkhedkar, Pankaj, Sarade, Girish, Purandare, Bharat, Kelkar, Dhananjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983476/
https://www.ncbi.nlm.nih.gov/pubmed/35400975
http://dx.doi.org/10.1016/j.jaim.2022.100575
_version_ 1784681983625920512
author Wanjarkhedkar, Pankaj
Sarade, Girish
Purandare, Bharat
Kelkar, Dhananjay
author_facet Wanjarkhedkar, Pankaj
Sarade, Girish
Purandare, Bharat
Kelkar, Dhananjay
author_sort Wanjarkhedkar, Pankaj
collection PubMed
description It has been 18 months now since the world-wide outbreak of COVID 19 (Corona Virus Disease 19) and still the ongoing research is being done for disease specific medicines. During June 2020 to August 2020, an attempt was made to explore if an add-on Ayurveda regimen comprising of Dasamoolkadutrayadi Kashayam and Guluchyadi Kwatham in tablet forms can be prescribed along with standard of care; which has established the clinical evidence that there is advantage of accelerated symptomatic recovery, early discharge from hospital, reducing the duration of hospital stay. After informed consent the patients were followed up over 9 months after discharged from hospital. The purpose of the present extended study was to find the impact of disease even though patients were discharged after appropriate treatment and if there were any late effects in the add-on Ayurveda treatment group after 9 months as it was one of the first few formal studies world-wide; since there was no long term follow up data available. The study concluded that no additional late effects or symptoms or complications which were known in Post COVID phase; were observed in study group who received the add-on Ayurveda regimen as compared to the control group with conventional standard of care.
format Online
Article
Text
id pubmed-8983476
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89834762022-04-06 The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen Wanjarkhedkar, Pankaj Sarade, Girish Purandare, Bharat Kelkar, Dhananjay J Ayurveda Integr Med Short Communication It has been 18 months now since the world-wide outbreak of COVID 19 (Corona Virus Disease 19) and still the ongoing research is being done for disease specific medicines. During June 2020 to August 2020, an attempt was made to explore if an add-on Ayurveda regimen comprising of Dasamoolkadutrayadi Kashayam and Guluchyadi Kwatham in tablet forms can be prescribed along with standard of care; which has established the clinical evidence that there is advantage of accelerated symptomatic recovery, early discharge from hospital, reducing the duration of hospital stay. After informed consent the patients were followed up over 9 months after discharged from hospital. The purpose of the present extended study was to find the impact of disease even though patients were discharged after appropriate treatment and if there were any late effects in the add-on Ayurveda treatment group after 9 months as it was one of the first few formal studies world-wide; since there was no long term follow up data available. The study concluded that no additional late effects or symptoms or complications which were known in Post COVID phase; were observed in study group who received the add-on Ayurveda regimen as compared to the control group with conventional standard of care. Elsevier 2022 2022-04-06 /pmc/articles/PMC8983476/ /pubmed/35400975 http://dx.doi.org/10.1016/j.jaim.2022.100575 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Wanjarkhedkar, Pankaj
Sarade, Girish
Purandare, Bharat
Kelkar, Dhananjay
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
title The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
title_full The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
title_fullStr The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
title_full_unstemmed The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
title_short The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
title_sort post-covid 19 long term surveillance study sequel to an add-on ayurveda regimen
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983476/
https://www.ncbi.nlm.nih.gov/pubmed/35400975
http://dx.doi.org/10.1016/j.jaim.2022.100575
work_keys_str_mv AT wanjarkhedkarpankaj thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen
AT saradegirish thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen
AT purandarebharat thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen
AT kelkardhananjay thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen
AT wanjarkhedkarpankaj postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen
AT saradegirish postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen
AT purandarebharat postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen
AT kelkardhananjay postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen